Exposome and Heredity Team, U1018, Universite Paris-Saclay, Universite Paris-Sud, CESP (Center for Research in Epidemiology and Population Health), Inserm, Villejuif, France.
Herault Cancer Registry, EA 2415, ICM, Montpellier, France.
Cancer Epidemiol Biomarkers Prev. 2022 Nov 2;31(11):2070-2078. doi: 10.1158/1055-9965.EPI-22-0302.
Sleep disturbances have been singled out for their implication in the risk of several cancer sites. However, results for prostate cancer are still inconsistent.
We used data from the EPICAP study, a French population-based case-control study including 819 incident prostate cancer cases and 879 controls frequency matched by age. Detailed information on sleep duration on work/free days, and sleep medication over lifetime was collected.
Sleep duration and sleep deprivation were not associated with prostate cancer, whatever the aggressiveness of prostate cancer. However, sleep deprivation was associated with an increased prostate cancer risk among men with an evening chronotype [OR, 1.96; 95% confidence interval (CI), 1.04-3.70]. We also observed an increased risk of prostate cancer with higher duration of sleep medication use (Ptrend = 0.008). This association with long duration of sleep medication use (≥10 years) was more pronounced among men who worked at night 15 years or more (OR, 3.84; 95% CI, 1.30-11.4) and among nonusers of NSAID (OR, 2.08; 95% CI, 1.15-3.75).
Our results suggested that chronotype, night work, or NSAID use could modify the association between sleep disorders and prostate cancer occurrence needing further investigations to go further.
EPICAP is the first study, which investigates several sleep indicators taking into account potential effect modifiers. If our findings were confirmed, we could identify subgroups of men at higher risk of prostate cancer that may be accessible to preventive measures.
睡眠障碍因其与几种癌症部位的风险有关而受到特别关注。然而，前列腺癌的结果仍不一致。
我们使用了 EPICAP 研究的数据，这是一项法国基于人群的病例对照研究，包括 819 例新发前列腺癌病例和 879 例按年龄匹配的对照。详细收集了工作/休息日的睡眠时间和终生睡眠药物使用情况。
无论前列腺癌的侵袭性如何，睡眠持续时间和睡眠剥夺与前列腺癌无关。然而，睡眠剥夺与夜间型生物钟男性的前列腺癌风险增加相关[OR，1.96；95%置信区间（CI），1.04-3.70]。我们还观察到使用睡眠药物时间较长（Ptrend = 0.008）与前列腺癌风险增加相关。这种与长时间使用睡眠药物（≥10 年）相关的关联在夜间工作 15 年或以上的男性（OR，3.84；95%CI，1.30-11.4）和非 NSAID 使用者中更为明显（OR，2.08；95%CI，1.15-3.75）。
我们的结果表明，生物钟、夜间工作或 NSAID 使用可能会改变睡眠障碍与前列腺癌发生之间的关联，需要进一步研究以进一步探讨。
EPICAP 是第一项研究，该研究考虑了潜在的调节因素，调查了几种睡眠指标。如果我们的发现得到证实，我们可以确定前列腺癌风险较高的男性亚组，这些亚组可能可以采取预防措施。
